Introduction
Up to 40% of adults with newly diagnosed acute myeloid leukaemia (AML) fail to attain a morphological complete remission (CR) after two cycles of induction chemotherapy. [1] [2] [3] The outlook for patients with primary refractory (PREF) AML is dismal, with no realistic prospect of long-term survival after salvage chemotherapy. 4 As a consequence, the development of new treatment strategies for PREF disease represents a major unmet need in adult AML. In the past two decades, it has been demonstrated that allogeneic stem cell transplantation from an HLA identical sibling has the capacity to deliver long-term disease free survival rates in the range of 20-30% in patients with PREF AML, [5] [6] [7] [8] but this treatment option is limited to a minority of patients who have a matched sibling donor. Considerable scepticism has been expressed as to whether transplantation from an alternative donor would be of any benefit in this patient population because of the challenges associated with the timely identification of an alternative donor and the anticipated mortality of unrelated transplantation in patients with active leukaemia. However, the recent rapid expansion in the size of unrelated donor registries has increased the availability of matched unrelated donors and results comparable to those obtained using a sibling donor are now achievable in patients with high risk AML transplanted in remission. 9 At the same time, advances in supportive care have significantly reduced the incidence and severity of infectious complications associated with induction chemotherapy, thereby increasing the proportion of patients with PREF AML eligible for allogeneic transplantation. As a consequence, unrelated donor transplantation is now technically feasible in large numbers of patients with PREF AML, but its ability to confer long-term disease-free survival has not previously been studied.
Patients and methods

Patient details
The outcome of 168 adults who underwent allogeneic stem cell transplantation for PREF AML, using a matched unrelated donor from 1994-2006 was reported to the European Group for Blood and Marrow Transplantation Registry. PREF disease was defined as failure to achieve a morphological CR in the bone marrow (BM) after two or more courses of induction chemotherapy. Patient details are described in Table 1 . Patients were transplanted from unrelated donors selected on the basis of serological typing at Class I (HLA-A and HLA-B) and molecular typing of Class II (DRB1) alleles. A matched unrelated donor was defined as the absence of an antigenic mismatch at Class I or a molecular mismatch at Class II. A total of 132 patients were transplanted using a myeloablative conditioning regimen, of whom 83 received a total body irradiation (TBI)-based regimen; 36 patients were transplanted using a reduced-intensity conditioning (RIC) regimen, as defined by the European Group for Blood and Marrow Transplantation criteria. 10 In 18 patients, the RIC regimen incorporated TBI at a dose of 4 Gy or less. All the 18 patients were transplanted using a RIC regimen, incorporating fludarabine in conjunction with melphalan, BCNU or busulphan, in the absence of low dose TBI. A total of 8 patients transplanted using a RIC regimen have been earlier reported by Schmid.
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Patient outcome and statistical analysis
Long-term follow-up data are available on all patients. The median duration of follow-up in live patients is 59 months (range 15-172 months). The main end-points of the study were overall survival (OS) defined as time to death from any cause and leukaemia-free survival (LFS) defined as time interval to first event (relapse or death). Acute graft-versus-host disease (GVHD) and chronic GVHD were graded according to standard criteria. All patients were considered assessable for acute GVHD after day þ 1. The presence of chronic GVHD was evaluated among patients who demonstrated sustained engraftment from day þ 100 post transplant.
Survival and LFS were calculated using the Kaplan-Meier estimate. 12 Non-relapse mortality and relapse incidence after CR were estimated by the cumulative incidence method, considering relapse and death in remission, respectively, as competing events, 13 only for patients who achieved a remission after transplantation considering as a starting point the day of acquisition of CR. Univariate analysis was done using the logrank test. In order to identify prognostic factors for OS and LFS after transplantation, multivariate analyses were performed using the Cox proportional hazards model, 14 including those variables with a P-value in the univariate analysis inferior to 0.15. Then a stepwise backward procedure was used with a cutoff significance level of 0.10 for deleting factors in the model. For all prognostic analyses, continuous variables were categorised and the median was used as a cut-off point. All tests are two-sided. The type I error rate was fixed at 0.05 for determination of factors associated with time to event outcomes. All statistical analyses were performed with SPSS (Chicago, IL, USA) and Splus 6.1 (MathSoft Inc., Cambridge, MA, USA) software packages.
Results
A total of 153 patients demonstrated neutrophil (40.5 Â 10 9 /l) engraftment at a median of 16 days (9-82) post transplant. The median time to achieving an absolute neutrophil count 40.5 Â 10 9 /l was 17 days (12-82) in recipients of a myeloablative conditioning allograft and 14 days (9-63) in patients transplanted using a RIC regimen. Primary graft failure was documented in 14 patients and one patient demonstrated secondary graft failure. Grade 2 or greater acute GVHD was documented in 73 patients. A total of 37 patients experienced grade III/IV acute GVHD. Chronic GVHD developed in 48 (43%) patients surviving more than 100 days.
With a median follow-up of 59 months, 37 patients were alive and free of leukaemia. The OS for the whole group was 26 and 22% at 2 and 5 years, respectively ( Figure 1a ). LFS was 23 and 20% at 2 and 5 years, respectively. In all, 118 patients achieved CR after transplant at a median time of 30 days (21-189 days); 50 patients failed to achieve CR, dying at a median of 50 days post transplant (4-395 days): 29 patients died of resistant disease, 13 failed to engraft and 8 died of transplant-related causes. For patients achieving a CR, the OS at 2 and 5 years was 35 and 31%, respectively. The relapse incidence in patients achieving a CR at 2 and 5 years was 45 and 47%, respectively. Donor lymphocyte infusions were administered to 28 patients. In 15 patients, donor lymphocyte infusions were administered as treatment of disease relapse. Abbreviations: BM, bone marrow; BSC, blood stem cell; CMV, cytomegalovirus; HLA, human leukocyte antigen; PB, peripheral blood; PREF AML, primary refractory acute myeloid leukaemia; SCT, stem cell transplantation; WBC, white blood cell.
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No patient who received donor lymphocyte infusions as treatment for disease relapse achieved remission and none were long-term survivors. Fifteen patients in this series underwent a second allogeneic transplant for treatment of disease relapse at a median of 7 months (range 2-31) after their original transplant for PREF AML. Only 2 patients are alive after a second allograft.
The results of the univariate analysis for survival are shown in Table 2 . In multivariate analysis, the following factors were associated with improved OS: fewer than three courses of induction chemotherapy (Hazard Ratio (HR): 1.66; 95% confidence interval (CI): 1.11-2.51; P ¼ 0.014), (Figure 1b) pre-transplant BM blast fewer than the median blast percentage (38.5%) (HR: 1.49; 95% CI: 1.01-2.18; P ¼ 0.04) (Figure 1c ) and patient cytomegalovirus (CMV) seropositivity (HR: 1.72; 95% CI: 1.15-2.59; P ¼ 0.009). The same factors were associated with an improved LFS: fewer than three courses of induction chemotherapy (HR: 1.63; 95% CI: 1.09-2.41; P ¼ 0.016), pretransplant blasts in the BM fewer than 38.5% (HR: 1.53; 95% CI: 1.05-2.24; P ¼ 0.027) and patient CMV seropositivity (HR: 1.67; 95% CI: 1.12-2.47; P ¼ 0.012). There was no impact of year of transplant on outcome.
We next assigned a score based on the summation of the number of adverse prognostic factors found to be significant by multivariate analysis: more than two induction course, pretransplant blasts in the BM more than the median (38.5%) and negative patient CMV serology. This allows delineation of four prognostic groups as follows: score 0 (no adverse prognostic factor): (n ¼ 22), 5 years OS: 44 ± 11% and 5 years LFS: 40±11%; score 1 (1 adverse prognostic factor): (n ¼ 47), 5 years OS: 24 ± 7% and 5years LFS 24 ± 7%; score 2 (2 adverse prognostic factors): (n ¼ 55), 5 years OS: 12±4 and 5years LFS: 10 ± 4%; score 3 (3 adverse prognostic factors) (n ¼ 11), 5 years OS 0% and 5years LFS 0%, respectively ( Figure 2 ).
Discussion
This study identifies unrelated donor transplantation as an important, potentially curative, treatment option in a significant proportion of patients with PREF AML. It is inevitable that the population of patients we have studied represent a selected subgroup, who were adjudged fit enough to proceed to transplant and had an available unrelated donor. However, advances in supportive care have significantly increased the proportion of patients with refractory AML who are eligible for transplant. At the same time, recent expansion in the size of unrelated donor registries has increased the probability of identifying a suitably matched unrelated donor in a timely manner. As a consequence, allogeneic transplantation is now technically feasible in a significant number of patients who lack a sibling donor and our data therefore establish unrelated donor transplantation as an important novel therapy in patients with PREF AML. Furthermore, the identification of factors predicting favourable long-term outcome provides a basis by which patients who will benefit from unrelated donor transplantation can be defined. It will also be important, in this patient population, to analyse the impact of pre-transplant co-morbidities on patient Unrelated donor transplantation in primary refractory AML C Craddock et al outcome. 15 At the same time, our data also identify a population of patients in whom transplantation appears to be almost futile, which allows patients to be counselled appropriately and, importantly, facilitates the responsible procurement of haematopoietic stem cells from unrelated donors.
In this study, three factors predicting long-term survival were defined: the number of courses of chemotherapy administered before the transplant, the leukaemic burden at the time of transplant and patient CMV serostatus. By incorporating these factors into a prognostic score, it is possible to identify patients with 5-year survival rates ranging from 44 to 0%. Although this scoring system requires validation, it provides a basis for future prospective studies in this sizeable cohort of patients. Our data identify proceeding to transplant, as early as possible, to be the most important manipulable factor determining outcome after unrelated donor transplantation in PREF disease. It is therefore vitally important to tissue type all patients with AML at diagnosis and initiate an urgent unrelated donor search in patients, failing to respond to their first course of induction chemotherapy, who lack a matched sibling donor. Our data did not demonstrate any difference in outcome between patients transplanted using an unrelated donor matched at 6/6 antigens compared with a donor with a single mismatch. This contrasts with studies performed in patients with standard risk leukaemia and further analysis of the impact of molecular mismatching at MHC Class 1 and Class II alleles will be of interest. 9, 16 The improved outcome of CMV positive patients in this study is consistent with reports of lower relapse rates after unrelated donor transplantation in CMV positive patients in a small number of other studies. 17, 18 In patients with standard risk disease, patient CMV seropositivity has earlier been associated with decreased survival after unrelated donor transplantation. 19 However, it is possible that an increased anti-tumour effect exerted in CMV positive patients, because of its association with increased alloreactivity or accelerated expansion of natural killer cells, disease is only detectable in patients at a high risk of disease relapse. 20, 21 Consistent with this hypothesis, we noted a trend towards a higher remission rate post transplant (75 versus 62% P ¼ 0.06), but no impact on either the incidence of acute GVHD was observed. In this context, the recent demonstration in a murine xenograft model that gd T cells, reactive against cytomegalovirus infected cells, exhibit anti-tumour activity is of interest. 22 The major cause of treatment failure in patients allografted for refractory AML is disease relapse. In this study, pre-transplant tumour burden is identified as an important determinant of relapse. It is not possible to determine whether this is a reflection of underlying disease biology, although presentation karyotype was not shown to influence outcome and it will therefore be relevant to study whether more intensive chemotherapy regimens, delivered either before or as part of the preparative Figure 2 Overall survival (OS) of study population according to scoring system: one point assigned to patients who had received more than two induction courses, one point assigned to patients with more pre-transplant blasts in the bone marrow (BM) than the median and one point assigned to patients with seronegative CMV serology.
Unrelated donor transplantation in primary refractory AML C Craddock et al regimen, might be effective in reducing disease relapse. Support for such an approach is provided by the observation that within the subgroup of patients who received only two courses of chemotherapy before transplant, outcome was improved if at least one of these courses contained high-dose cytosine arabinoside (5-year OS: 40 versus 21%; P ¼ 0.02). In this context, it is relevant to note that neither the use of TBI nor the irradiation dose was noted to impact on patient survival in patients transplanted using a myeloablative preparative regimen. There is abundant evidence of a potent graft-versusleukaemia effect in patients allografted for AML in remission, but its contribution to disease-free survival in patients with PREF disease is unknown. It is therefore worthy of note that a trend for increased survival was observed in patients with grade 2 or greater acute GVHD, supporting the deployment of strategies that can optimise a graft-versus-leukaemia effect in this patient population.
To date, the outcome of older patients with PREF AML after a reduced intensity, unrelated donor transplant has not been reported. Given the increased incidence of primary induction failure in older patients and the scarcity of sibling donors, our data identifies reduced intensity unrelated donor transplantation as a potentially important new treatment modality in this sizeable patient population. The observation that long-term survival can be obtained using either low dose TBI or fludarabine-based reduced intensity preparative regimen requires further investigation in the setting of a prospective trial. The apparent discrepancy in survival after reduced intensity allografts between patients transplanted for PREF and those transplanted for refractory relapse disease is further evidence that these disease entities may demonstrate sharply differing susceptibilities to transplantation and underlines the importance of analysing them separately. Further studies addressing the difference in outcome between patients with PREF AML and relapsed disease are indicated with particular reference to a potential difference in their susceptibility to a graft-versusleukaemia effect.
In conclusion, our data supports further examination of the role of unrelated donor transplantation in the management of patients with PREF AML and confirms this to be a potentially curative option in an increasingly large proportion of patients for whom no other effective treatment currently exists. Pretransplant characteristics assist in identifying patients most likely to benefit from transplantation and early identification of a suitable unrelated donor is essential if transplant outcome is to be optimised. Furthermore, reduced intensity transplantation using an unrelated donor is a potentially important new treatment strategy for older patients with PREF AML.
